Gastroesophageal Reflux Disease and Alkaline Reflux: the Mechanisms of the Development and Therapeutic Approach

T.D. Zviahintseva, I.I. Sharhorod

Abstract


The article deals with gastroesophageal reflux disease (GERD) — a pathology, which occupies a leading place among all acid-related diseases. The main mechanism of GERD is a violation of the motor-evacuation function of the stomach — slowing gastric emptying and duodenogastric reflux. Slow gastric emptying contributes to more frequent reflux, and the presence of duodenal contents in refluxate — alkaline reflux — is aggressive for the esophageal mucosa (EM). This is due to the presence of bile acids, lysolecithin and pancreatic enzymes in the esophageal refluxate. A long existing contact of aggressive factors in the stomach and the esophagus leads to the development of inflammatory and destructive lesions of the mucous membrane of these organs. According to many researchers, bile acids play a key role in the pathogenesis of the damaging effects on the EM. Drug correction of GERD with alkaline reflux includes, along with the administration of proton pump inhibitors, prokinetics (itopride hydrochloride) and ursodeoxycholic acid preparations.


Keywords


gastroesophageal reflux disease; bile acids; esophageal mucosa; proton pump inhibitor; prokinetic; ursodeoxycholic acid

References


Katz P.O., Gerson L.B., Vela M.F. Guidelines for the Diagnosis and Management of Gastroesofageal Reflux Disease // The American Journal of Gastroenterology. — 2013. — ​Vol. 108. — ​P. 308-328.

Thrift A.P., Kramer J.R., Qureshi Z., Richardson P.A., El-Serag H.B. Age at Onset of GERD Symptoms Predicts Risk of Barrett’s Esophagus // Am. J. Gastroenterol. — 2013. — 108 (6). — 915-922.

Oryu M., Mori H., Kobara H. et al. Differences in the Characteristics of Barrett’s Esophagus and Barrett’s Adenocarcinoma between the United States and Japan, ISRN // Gastroenterology. — 2013. — ​V. 2013. Article ID840690, 8 p.

El-Serag Н.В., Sweet S., Winchester С.С., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review // Gut. — 2013. — ​doi. — 10.1136/gutjnl‑2012-304269.

Маев И.В., Андреев Д.Д., Дичева Д.Т. Гастроэзофагеальная рефлюксная болезнь: от патогенеза к терапевтическим аспектам // Cons. Med. — 2013. — 8. — 30-4.

Vaezi M.F., Richter J.E. Role of acid and duodenogastroe-sophageal reflux in gastroesophageal reflux disease // Gastroente­rology. — 1996. — 111 (5). — 1192-1199.

Moraes-Filho J.P. Refractory gastroesophageal reflux di­sease // Arq. Gastroenterol. — 2012. — 49 (4). — 296-301.

Mabrut J.Y., Collard J.M., Baulieux J. Duodenogastric and gastroesophageal bile reflux // J. Chir. (Paris). — 2006 Nov-Dec. — 143 (6). — 355-65.

Moraes-Filho J.P. Refractory gastroesophageal reflux di­sease // Arq. Gastroenterol. — 2012. — 49 (4). — 296-301.

Dixon M., Neville P., Mapsfone N. et al. Bile reflux gastritis and Barrett’s esophagus: Further evidence of a role for duodenogastroesop-hageal reflux // Gut. — 2001. — 49. — 359-63.

McColl K.E., Clarke A., Seenan J. Acid pocket, hiatus hernia and acid reflux // Gut. — 2010, Apr. — 59 (4). — 430-431.

McQuaid K.R., Laine L., Fennerty M.B. et al. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia // Aliment. Pharmacol. Ther. — 2011. — 34. — 146-65.

Hong J., Behar J., Wands J. et al. Role of a novel bile acid receptor TGR5 in the development of oesophageal adenocarcinoma // Gut. — 2010. — 59. — 170-80.

Nehra D., Howell P., Williams C.P. et al. Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity // Gut. — 1999. — 44. — 598-602.

Oh D.S., Hagen J.A., Fein M. et al. The impact of reflux composition on mucosal injury and esophageal function // Journal of Gastrointestinal Surgery. — 2005. — 10. — 87-797.

Кучерявый Ю.А, Андреев Д.Н. Перспективы лечения больных с кислотозависимыми заболеваниями // Клин. перспективы гастроэнтерологии, гепатологии. — 2014. — 2. — 15-24.

Tack J. Prokinetics and fundic relaxants in upper functional GI disorders // Curr. Opin Pharmacol. — 2008 Dec. — 8 (6). — 690-6. Epub 2008 Oct 27.

Lim H.C., Kim Y.G., Lim J.H., Kim H.S., Park H. Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro // Yonsei Med. J. — 2008 Jun 30. — 49 (3). — 472-8.

Маев И.В., Дичева Д.Т., Андреев Д.Н. и др. Терапевтическая роль прокинетических препаратов в лечении гастроэзофагеальной рефлюксной болезни // Мед. совет. — 2014. — 4. — 66-70.

Yao-Kuang Wang, Wen-Hung Hsu, Sophie S.W. Wang et al. Current Pharmacological Management of Gastroesophageal Reflux Disease // Gastroenterology Research and Practice. — 2013. — ​V. 2013. Article ID983653, 12 p.

Scarpellini E., Vos R., Blondeau K. et al. The effects of itoprid on esophageal motility and lower esophageal sprinter function in man // Aliment. Pharmacol. Ther. — 2011. — 33. — 99-105.

Amaral J.D., Viana R.J., Ramalho R.M., Steer C.J., Rodrigues C.M. Bile acids: regulation of apoptosis by ursodeoxycholic acid // Journal of Lipid Research. — 2009. — 50 (9). — 1721-34.

Буеверов А.О. Возможности клинического применения урсодезоксихолевой кислоты // Cons. Med. — 2008. — 6. — 460-3.

Лапина Т.Л., Картавенко И.М. Урсодезоксихолевая кислота: влияние на слизистую оболочку верхних отделов желудочно-кишечного тракта // Рос. журн. гастроэнтерол., гепатол., колопроктол. — 2007. — № 6. — ​С. 51-7.




DOI: https://doi.org/10.22141/2308-2097.4.62.2016.81087

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru